Yali Dou

Title(s)Professor of Medicine
SchoolKeck School of Medicine of Usc
Address1441 Eastlake Ave. NTT 3416
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard
    Other Positions
    Title(s)Marion and Harry Keiper Chair in Cancer Research

    Title(s)Co-Director of the Ph.D. Program in Molecular Medicine

    Title(s)Co-Director of the USC Norris Brown Center for Cancer Drug Development


    Collapse Overview 
    Collapse Overview
    Dr. Yali Dou is a Professor in the Department of Medicine and Department of Biochemistry and Molecular Medicine. She is Marion and Harry Keiper Endowed Professor for cancer research. Dr. Dou is the Associate Director for Basic Science at Norris Comprehensive Cancer Center.

    Dr. Dou has received a number of prestigious awards including the Leukemia & Lymphoma Society Scholar Award (2012), Stand Up to Cancer IRG Award (2011), AACR Gertrude B. Elion Cancer Research Award (2010) and Dean’s Award in Basic Science at University of Michigan (2014).

    Research Interests
    Cell fate decisions are controlled by transcription factors acting in concert with epigenetic regulators, which include enzymes that carry out histone post-translational modifications. Epigenetic mechanism underlies cell fate commitment and plasticity; its dysregulation emerges as a key characteristic of human malignancies. The Dou lab uses multidisciplinary approaches to study the establishment and maintenance of gene regulatory networks, focusing on how chromatin modifications exert temporal and spatial gene regulation via transcription factors and DNA regulatory elements. The lab is also interested in the interplays between chromatin modifications and other important cellular processes, including metabolic regulation, genome stability and higher order chromatin organization. In particular, Dou lab has extensive research on the MLL/KMT2 family of histone methyltransferases. MLL/KMT2 deposit histone H3 lysine 4 methylation, which prominently marks active gene promoters and distal enhancers. The MLL/KMT2 enzymes are frequently deleted, mutated or translocated in acute leukemia, solid tumors as well as a wide spectrum of human developmental syndromes. The study will not only advance understanding of the fundamental roles of epigenetic modulators in development and diseases, but also provide critical insights into designing novel target-based therapeutic strategies for cancer treatment and regenerative medicine.

    Collapse Research 
    Collapse Research Activities and Funding
    Structural insights into the MLL core complexes
    NIH R01CA250329Aug 25, 2020 - May 31, 2025
    Role: Principal Investigator
    Enhancer Dysregulation in AML
    NIH R01CA232263Mar 1, 2019 - Feb 29, 2024
    Role: Principal Investigator
    PRDM16 function in neural development
    NIH R01NS100156Sep 1, 2016 - Aug 31, 2021
    Role: Principal Investigator
    Chromatin replication control by protein ubiquitylation
    NIH R21CA190911Aug 7, 2015 - Jul 31, 2017
    Role: Principal Investigator
    Targeting MLL3 histone methyltransferase
    NIH R01CA187004Apr 15, 2015 - Mar 31, 2018
    Role: Principal Investigator
    Cytokine-induced epigenetic changes during chronic lung disease
    NIH R01HL112897Jun 15, 2013 - May 31, 2017
    Role: Co-Principal Investigator
    Targeting the MLL-WDR5 protein-protein interaction
    NIH R01CA177307Apr 9, 2013 - Mar 31, 2018
    Role: Co-Principal Investigator
    Function of MLL in transcription regulation
    NIH R01GM082856Apr 1, 2009 - Apr 30, 2024
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Author Correction: Quiescence enables unrestricted cell fate in naive embryonic stem cells. Nat Commun. 2024 Mar 12; 15(1):2215. Khoa LTP, Yang W, Shan M, Zhang L, Mao F, Zhou B, Li Q, Malcore R, Harris C, Zhao L, Rao RC, Iwase S, Kalantry S, Bielas SL, Lyssiotis CA, Dou Y. PMID: 38472240; PMCID: PMC10933312.
      View in: PubMed   Mentions:    Fields:    
    2. Quiescence enables unrestricted cell fate in naive embryonic stem cells. Nat Commun. 2024 Feb 26; 15(1):1721. Khoa LTP, Yang W, Shan M, Zhang L, Mao F, Zhou B, Li Q, Malcore R, Harris C, Zhao L, Rao RC, Iwase S, Kalantry S, Bielas SL, Lyssiotis CA, Dou Y. PMID: 38409226; PMCID: PMC10897426.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    3. Non-canonical MLL1 activity regulates centromeric phase separation and genome stability. Nat Cell Biol. 2023 Nov; 25(11):1637-1649. Sha L, Yang Z, An S, Yang W, Kim S, Oh H, Xu J, Yin J, Wang H, Lenz HJ, An W, Cho US, Dou Y. PMID: 37945831.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    4. Modeling kidney development, disease, and plasticity with clonal expandable nephron progenitor cells and nephron organoids. bioRxiv. 2023 May 25. Huang B, Zeng Z, Li H, Li Z, Chen X, Guo J, Zhang CC, Schreiber ME, Vonk AC, Xiang T, Patel T, Li Y, Parvez RK, Der B, Chen JH, Liu Z, Thornton ME, Grubbs BH, Diao Y, Dou Y, Gnedeva K, Lindström NO, Ying Q, Pastor-Soler NM, Fei T, Hallows KR, McMahon AP, Li Z. PMID: 37293038; PMCID: PMC10245960.
      View in: PubMed   Mentions:
    5. Structural insights on the KMT2-NCP interaction. Biochem Soc Trans. 2023 02 27; 51(1):427-434. Yang Z, Zepeda R, Dou Y. PMID: 36695549.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    6. Dissecting MENIN in bivalent gene regulation. Nat Cell Biol. 2023 02; 25(2):209-210. Wang XQD, Dou Y. PMID: 36635502.
      View in: PubMed   Mentions:    Fields:    
    7. Dysregulation of intercellular signaling by MOF deletion leads to liver injury. J Biol Chem. 2021 Jan-Jun; 296:100235. Lei H, denDekker AD, Li G, Zhang Z, Sha L, Schaller MA, Kunkel SL, Rui L, Tao K, Dou Y. PMID: 33376138; PMCID: PMC7948572.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    8. Histone Acetyltransferase MOF Blocks Acquisition of Quiescence in Ground-State ESCs through Activating Fatty Acid Oxidation. Cell Stem Cell. 2020 09 03; 27(3):441-458.e10. Khoa LTP, Tsan YC, Mao F, Kremer DM, Sajjakulnukit P, Zhang L, Zhou B, Tong X, Bhanu NV, Choudhary C, Garcia BA, Yin L, Smith GD, Saunders TL, Bielas SL, Lyssiotis CA, Dou Y. PMID: 32610040; PMCID: PMC7758074.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    9. Cryo-EM structure of the human MLL1 core complex bound to the nucleosome. Nat Commun. 2019 12 05; 10(1):5540. Park SH, Ayoub A, Lee YT, Xu J, Kim H, Zheng W, Zhang B, Sha L, An S, Zhang Y, Cianfrocco MA, Su M, Dou Y, Cho US. PMID: 31804488; PMCID: PMC6895043.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    10. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer Cell. 2018 10 08; 34(4):643-658.e5. Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, Dou Y, Hess JL. PMID: 30270123; PMCID: PMC6179449.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    11. MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency. Cell Stem Cell. 2016 Apr 07; 18(4):481-94. Zhang H, Gayen S, Xiong J, Zhou B, Shanmugam AK, Sun Y, Karatas H, Liu L, Rao RC, Wang S, Nesvizhskii AI, Kalantry S, Dou Y. PMID: 26996599; PMCID: PMC4826731.
      View in: PubMed   Mentions: 41     Fields:    Translation:AnimalsCells
    12. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015 Jun; 15(6):334-46. Rao RC, Dou Y. PMID: 25998713; PMCID: PMC4493861.
      View in: PubMed   Mentions: 284     Fields:    Translation:Humans
    13. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell. 2014 Jan 23; 53(2):247-61. Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, Liu L, Chen Y, Ouillette P, Zhu J, Hess JL, Atadja P, Lei M, Qin ZS, Malek S, Wang S, Dou Y. PMID: 24389101; PMCID: PMC3965208.
      View in: PubMed   Mentions: 159     Fields:    Translation:HumansAnimalsCells
    14. The histone acetyltransferase MOF is a key regulator of the embryonic stem cell core transcriptional network. Cell Stem Cell. 2012 Aug 03; 11(2):163-78. Li X, Li L, Pandey R, Byun JS, Gardner K, Qin Z, Dou Y. PMID: 22862943; PMCID: PMC3413170.
      View in: PubMed   Mentions: 118     Fields:    Translation:AnimalsCells
    Yali's Networks
    Concepts (72)
    Derived automatically from this person's publications.
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _